NXTC – Nextcure Inc
Float Short %
3.03
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
1.37
EPS Last/This Y
10.15
EPS This/Next Y
5.5
Price
14.08
Target Price
17.67
Analyst Recom
1
Performance Q
37.3
Upside
-6,266.4%
Beta
1.48
Ticker: NXTC
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | NXTC | 11.9 | N/A | N/A | 0 |
| 2026-01-26 | NXTC | 12.4 | N/A | N/A | 0 |
| 2026-01-27 | NXTC | 11.12 | N/A | N/A | 0 |
| 2026-01-28 | NXTC | 10.83 | N/A | N/A | 0 |
| 2026-01-29 | NXTC | 10.43 | N/A | N/A | 0 |
| 2026-01-30 | NXTC | 10.94 | N/A | N/A | 0 |
| 2026-02-02 | NXTC | 10.91 | N/A | N/A | 0 |
| 2026-02-03 | NXTC | 11.16 | N/A | N/A | 0 |
| 2026-02-04 | NXTC | 11.96 | N/A | N/A | 0 |
| 2026-02-05 | NXTC | 11.09 | N/A | N/A | 0 |
| 2026-02-06 | NXTC | 11.13 | N/A | N/A | 0 |
| 2026-02-09 | NXTC | 11.89 | N/A | N/A | 0 |
| 2026-02-10 | NXTC | 12.32 | N/A | N/A | 0 |
| 2026-02-11 | NXTC | 12.35 | N/A | N/A | 0 |
| 2026-02-12 | NXTC | 13 | N/A | N/A | 0 |
| 2026-02-13 | NXTC | 13.03 | N/A | N/A | 0 |
| 2026-02-17 | NXTC | 12.91 | N/A | N/A | 0 |
| 2026-02-18 | NXTC | 13.12 | N/A | N/A | 0 |
| 2026-02-20 | NXTC | 14.05 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | NXTC | 11.90 | 53.5 | 18.9 | -13.73 |
| 2026-01-26 | NXTC | 12.20 | 53.5 | 10.5 | -13.73 |
| 2026-01-27 | NXTC | 11.31 | 53.5 | 21.2 | -13.73 |
| 2026-01-28 | NXTC | 10.74 | 53.5 | 18.2 | -13.73 |
| 2026-01-29 | NXTC | 10.69 | 53.5 | 12.5 | -13.73 |
| 2026-01-30 | NXTC | 10.94 | 53.5 | 5.4 | -13.73 |
| 2026-02-02 | NXTC | 11.23 | 53.5 | 5.9 | -13.73 |
| 2026-02-03 | NXTC | 11.38 | 53.5 | 6.2 | -13.73 |
| 2026-02-04 | NXTC | 11.90 | 53.5 | 2.6 | -13.73 |
| 2026-02-05 | NXTC | 11.37 | 53.5 | 19.5 | -13.73 |
| 2026-02-06 | NXTC | 11.20 | 53.5 | 12.7 | -13.73 |
| 2026-02-09 | NXTC | 11.81 | 53.5 | 2.9 | -13.73 |
| 2026-02-10 | NXTC | 12.31 | 53.5 | 8.1 | -13.73 |
| 2026-02-11 | NXTC | 12.40 | 53.5 | 11.2 | -13.73 |
| 2026-02-12 | NXTC | 13.05 | 53.5 | 8.6 | -13.73 |
| 2026-02-13 | NXTC | 13.12 | 53.5 | 11.6 | -13.73 |
| 2026-02-17 | NXTC | 12.91 | 53.5 | 14.4 | -13.73 |
| 2026-02-18 | NXTC | 13.07 | 53.5 | 10.7 | -13.73 |
| 2026-02-19 | NXTC | 14.07 | 53.5 | - | -13.73 |
| 2026-02-20 | NXTC | 14.08 | 53.5 | - | -13.73 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-26 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-27 | NXTC | 0.00 | 7.18 | 1.71 |
| 2026-01-28 | NXTC | 0.00 | 7.18 | 2.55 |
| 2026-01-29 | NXTC | 0.00 | 7.18 | 2.55 |
| 2026-01-30 | NXTC | 0.00 | 7.18 | 2.55 |
| 2026-02-02 | NXTC | 0.00 | 7.18 | 2.55 |
| 2026-02-03 | NXTC | 0.00 | 7.18 | 3.08 |
| 2026-02-04 | NXTC | 0.00 | 7.18 | 3.08 |
| 2026-02-05 | NXTC | 0.00 | 7.18 | 3.08 |
| 2026-02-06 | NXTC | 0.00 | 7.18 | 3.08 |
| 2026-02-10 | NXTC | 0.00 | 8.49 | 3.08 |
| 2026-02-11 | NXTC | 0.00 | 8.49 | 3.03 |
| 2026-02-12 | NXTC | 0.00 | 8.49 | 3.03 |
| 2026-02-13 | NXTC | 0.00 | 8.49 | 3.03 |
| 2026-02-17 | NXTC | 0.00 | 4.62 | 3.03 |
| 2026-02-18 | NXTC | 0.00 | 4.62 | 3.03 |
| 2026-02-19 | NXTC | 0.00 | 4.62 | 3.03 |
| 2026-02-20 | NXTC | 0.00 | 4.62 | 3.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-3.22
Avg. EPS Est. Current Quarter
-2.29
Avg. EPS Est. Next Quarter
-1.85
Insider Transactions
Institutional Transactions
4.62
Beta
1.48
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
3
Growth Score
19
Sentiment Score
88
Actual DrawDown %
91.3
Max Drawdown 5-Year %
-98
Target Price
17.67
P/E
Forward P/E
PEG
P/S
P/B
1.55
P/Free Cash Flow
EPS
-24.19
Average EPS Est. Cur. Y
-13.73
EPS Next Y. (Est.)
-8.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.62
Return on Equity vs Sector %
-274.3
Return on Equity vs Industry %
-256.9
EPS 1 7Days Diff
0.6
EPS 1 30Days Diff
1.86
EBIT Estimation
NextCure, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading